TITLE

Candesartan reduced mortality and hospital admissions in chronic heart failure: COMMENTARY

AUTHOR(S)
Pitt, Bertram
PUB. DATE
March 2004
SOURCE
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on the study conducted to analyses the efficacy of Candesartan to reduce mortality and hospital admissions in chronic heart failure (CHF). The study extends the knowledge of the role of angiotensin-receptor blocker (ARBs) in patients with CHF. It is likely mat ARBs used at the appropriate dose, such as valsartan 160 mg twice daily or candesartan 32 mg daily, are equivalent to target doses of an ACE inhibitor, such as enalapril 10 mg twice daily. In patients with severe heart failure, an aldosterone blocker might be the preferred agent to add to an ACE inhibitor and a β-blocker rather than an ARB based on the results of a study.
ACCESSION #
12597115

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics